Physician profile
Peter Szeto
NPI 1003862889
$1,063.16
in general payments reported to CMS, 2019-2025
16 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2021: $64.33 · 2022: $415 · 2023: $240 · 2024: $110 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $245.81 | 2022-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $212.94 | 2021-2023 | |
| Novo Nordisk INC | $180.76 | 2024-2025 | Wegovy |
| Astellas Pharma US INC | $102.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.57 | 2022 | |
| Medtronic, INC. | $45.02 | 2022-2024 | Mosaic |
| Irhythm Technologies, INC. | $38.49 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $38.35 | 2022-2023 | Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.74 | 2022 | |
| Pfizer INC. | $18.44 | 2023 | |
| Abbott Laboratories | $15.97 | 2021 | |
| Merck Sharp & Dohme LLC | $15.67 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $15.63 | 2021 | |
| Amgen INC. | $15.44 | 2022 | |
| Ethicon US, LLC | $13.29 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Szeto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.